Skip to main content
. 2024 Apr 8;16(1):97–101. doi: 10.1159/000536483

Fig. 2.

Fig. 2.

Improvement of cutaneous lesions after 15 months of follow-up, with combined siltuximab and 1,927 nm fractional laser treatment (ad); dermoscopy showing reduction of erythema, with central scarring area and peripheral hyperpigmentation, in the setting of dermatofibroma-like pattern (e); RCM showing only fibrotic bundles with remodeling of superficial dermis in absence of hyper-reflective inflammatory cells (f).